Cempra Inc. shares (NASDAQ:CEMP) rose 28.6 percent to $4.05 on Friday as the company reported that early clinical responses to its oral antibiotic, Taksta (fusidic acid), proved noninferior to those for Pfizer Inc.’s oral Zyvox (linezolid) during a phase III trial, meeting the primary endpoint.